Compare Johnson & Johnson (JNJ) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Payoneer Global Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Payoneer Global Inc trades at $7.14 (market cap $2.43B). The key difference: Johnson & Johnson is far larger — about 254.4× Payoneer Global Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Payoneer Global Inc for 61 Days on average.
| JNJ | PAYO | |
|---|---|---|
Market Cap | $618.09B | $2.43B |
Volume | 6,050,983 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $278.43 | $7.18 |
52-Week Low | $186.00 | $4.27 |
Typical Hold Time | 129 Days | 61 Days |
Enterprise Value | $646.37B | $2.17B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Payoneer Global (PAYO) trades at $7.16 with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q2 2026 earnings of $0.02 per share, missing estimates of $0.05761, though revenue grew 10% year-over-year excluding interest. Recent developments include the renewal of its partnership with Etsy through 2029 and expansion of its India innovation hub.
The pending acquisition by Nuvei creates uncertainty, but analyst sentiment remains positive with 60% buy ratings. Key risks include integration challenges from the acquisition and competitive pressures in the fintech sector, while opportunities lie in continued B2B growth and international expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
